These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38452732)

  • 1. Explainable AI-based Deep-SHAP for mapping the multivariate relationships between regional neuroimaging biomarkers and cognition.
    Bhattarai P; Thakuri DS; Nie Y; Chand GB
    Eur J Radiol; 2024 May; 174():111403. PubMed ID: 38452732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminating Aging Cognitive Decline Spectrum Using PET and Magnetic Resonance Image Features.
    Dartora CM; de Moura LV; Koole M; Marques da Silva AM;
    J Alzheimers Dis; 2022; 89(3):977-991. PubMed ID: 35988218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XGBoost-SHAP-based interpretable diagnostic framework for alzheimer's disease.
    Yi F; Yang H; Chen D; Qin Y; Han H; Cui J; Bai W; Ma Y; Zhang R; Yu H
    BMC Med Inform Decis Mak; 2023 Jul; 23(1):137. PubMed ID: 37491248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using
    Li J; Zheng C; Ge Q; Yan S; Paranjpe MD; Hu S; Zhou Y;
    J Neurosci Res; 2022 Feb; 100(2):670-680. PubMed ID: 34882830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.
    Kamagata K; Andica C; Takabayashi K; Saito Y; Taoka T; Nozaki H; Kikuta J; Fujita S; Hagiwara A; Kamiya K; Wada A; Akashi T; Sano K; Nishizawa M; Hori M; Naganawa S; Aoki S;
    Neurology; 2022 Dec; 99(24):e2648-e2660. PubMed ID: 36123122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting changes in brain metabolism and progression from mild cognitive impairment to dementia using multitask Deep Learning models and explainable AI.
    García-Gutiérrez F; Hernández-Lorenzo L; Cabrera-Martín MN; Matias-Guiu JA; Ayala JL;
    Neuroimage; 2024 Aug; 297():120695. PubMed ID: 38942101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Diadem: a constrained dual-input deep learning model to identify novel biomarkers in Alzheimer's disease.
    Jemimah S; AlShehhi A;
    BMC Med Genomics; 2023 Oct; 16(Suppl 2):244. PubMed ID: 37833700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
    Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
    Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
    Ten Kate M; Redolfi A; Peira E; Bos I; Vos SJ; Vandenberghe R; Gabel S; Schaeverbeke J; Scheltens P; Blin O; Richardson JC; Bordet R; Wallin A; Eckerstrom C; Molinuevo JL; Engelborghs S; Van Broeckhoven C; Martinez-Lage P; Popp J; Tsolaki M; Verhey FRJ; Baird AL; Legido-Quigley C; Bertram L; Dobricic V; Zetterberg H; Lovestone S; Streffer J; Bianchetti S; Novak GP; Revillard J; Gordon MF; Xie Z; Wottschel V; Frisoni G; Visser PJ; Barkhof F
    Alzheimers Res Ther; 2018 Sep; 10(1):100. PubMed ID: 30261928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S; Passamonti L; Duggento A; Liò P; Toschi N;
    Neuroimage; 2019 Apr; 189():276-287. PubMed ID: 30654174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.